26 citations
,
September 2018 in “Neurobiology of Disease” This study found that both finasteride and dutasteride significantly reduced L-DOPA-induced dyskinesia in a rat model of Parkinson's disease, with dutasteride showing greater effectiveness at lower doses.
15 citations
,
January 2017 in “Experimental Neurology” This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.
2 citations
,
March 2023 in “Experimental neurology” In this study, pregnenolone was found to dose-dependently reduce L-DOPA-induced dyskinesias in a rat model of Parkinson's disease, suggesting its potential as a therapeutic target for these dyskinesias.
September 2024 in “Frontiers in Neuroendocrinology” In this review, the researchers reported that 5α-reductase inhibitors demonstrated neuroprotective effects and reduced dyskinesias in animal models of Parkinson's disease, suggesting their potential for repurposing to manage symptoms in men with PD.
February 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” This study found that Prss53-mutated rabbits exhibited curved hair and skeletal dyskinesia, suggesting a link between Prss53 loss and these traits, potentially involving disrupted calcium metabolism.